| 15801844 |
Lopez-Rodriguez ML, Morcillo MJ, Fernandez E, Benhamu B, Tejada I, Ayala D, Viso A, Campillo M, Pardo L, Delgado M, Manzanares J, Fuentes JA: Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. J Med Chem. 2005 Apr 7;48(7):2548-58.
Computational simulation of ligand-receptor interaction of 5-HT (1A) R agonists with selectivity over alpha1-adrenoceptors.. We have designed and synthesized a new series of arylpiperazines V exhibiting high 5-HT (1A) R affinity and selectivity over alpha (1)-adrenoceptors. The new selective 5-HT (1A) R ligands contain a hydantoin (m = 0) or diketopiperazine (m = 1) moiety and an arylpiperazine moiety separated by one methylene unit (n = 1). The aryl substituent of the piperazine moiety (Ar) consists of different benzofused rings mimicking the favorable voluminous substituents at ortho and meta positions predicted by 3D-QSAR analysis in the previously reported series I. In particular, (S)-2-[[4-(naphth-1-yl) piperazin-1-yl] methyl]-1,4-dioxoperhydropyrrolo [1,2 -a] pyrazine [(S)-9, CSP-2503] (5-HT (1A), K (i) = 4.1 nM; alpha (1), K (i) > 1000 nM) has been pharmacologically characterized as a 5-HT (1A) R agonist at somatodendritic and postsynaptic sites, endowed with anxiolytic properties. Ligand (S)-9 is predicted, in computer simulations, to bind Asp (3.32) in TMH 3, Thr (5.39) and Ser (5.42) in TMH 5, and Trp (6.48) in TMH 6. We propose that agonists modify, by means of an explicit hydrogen bond, the conformation of Trp (6.48) from pointing toward TMH 7, in the inactive gauche+ conformation, to pointing toward the ligand binding site, in the active trans conformation. |
1(0,0,0,1) |